



LATE-BREAKING ABSTRACT SUBMISSION TERMS AND CONDITIONS 2024

Introduction

The EHA Late-Breaking Abstracts terms and conditions allows for the submission of abstracts containing clinical or non-clinical data which were incomplete at the time of the abstract submission deadline (March 1, 2024). For clinical trials a preplanned analysis of the primary endpoint should have been scheduled after this date.

Table of contents

General abstract terms	2
Abstract embargo policy	4
Timeline	5
Selection procedure	5
Abstract Topics	6
EHA Copyright	7



General abstract terms

The submitted abstracts should fully adhere to the guidelines below as well as the regulations applying to the regular abstract submission:

1. The Scientific Program Committee (SPC) only accepts original scientific material unpublished at the time of the abstract submission deadline. Abstracts containing previously published information will be rejected.
2. Abstracts previously submitted to large international meetings which are organized in the same period as the EHA Congress (May – July) are allowed to be submitted to the Congress. Examples of international meetings are the American Society of Clinical Oncology (ASCO), International Society of Thrombosis and Haemostasis (ISTH) and the International Congress on Malignant Lymphomas (ICML).
3. Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract; (i) in relation to the EHA Annual Congress and (ii) to be published and distributed in/on EHA websites, EHA's journal Hemasphere, portals, mobile learning apps, platforms, (digital) course material, (online) workshops, sessions at (online) conferences, other (online) meetings, or in whatever (new) electronic, printed, or other forms of communication. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
4. Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
5. By submitting an abstract the submitting author confirms that they have approval from all the co-authors to submit and use the data.
6. Submitted abstracts are considered embargoed from the time of submission (see embargo policy on page 4).
7. Abstracts accepted and presented during the EHA Annual Congress may be submitted as encore abstracts to meetings commencing after the Congress dates, with the reference that it has been accepted and presented at the EHA Annual Congress.
8. Case reports are generally not accepted unless they bring significant and novel biological information. In addition, single case abstracts will not be accepted.
9. The abstract title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts.
10. In clinical studies, please state whether informed consent was obtained.
11. If off label use of drugs was involved, please state this clearly.
12. Do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
13. Similarly to point 12, do not submit a copy or close copy of an abstract under more than 1 category. Abstracts that appear to be submitted multiple times under different categories will be rejected.



14. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar, syntax and spelling.
 15. The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
 16. Presenting authors of accepted abstracts are required to present their abstract in-person during the meeting.
 17. Presenting authors are not allowed to be company representatives.
 18. Abstracts submitted without any data will not be accepted or presented.
 19. Concept abstracts, for example new techniques or technologies without a demonstrated application will not be accepted.
- Withdrawal policy: If authors wish to withdraw their abstracts from presentation they are requested to send a letter via email to the congress secretariat before May 29. Consequently, the abstract will not be presented nor published.
 - Accepted late-breaking abstracts will be published via official EHA channels, including the Congress website as of Monday, June 3; 16:00 (CEST).



Abstract embargo policy

- Submitted abstracts are considered embargoed from the time of submission.
- The information contained in the abstracts is embargoed until the abstracts are made available online by EHA.
- All accepted late-breaking abstracts are embargoed until **Monday, June 3, 2024; 16:00 CEST**. On this date and time, they will be published via www.ehaweb.org.
- Coverage of information that goes beyond what is contained in the abstract (e.g. additional analysis, commentary, or updated information from those individuals and companies involved in the study) is embargoed according to the following criteria:
 - **For Plenary Abstracts Session presentations:** The embargo is lifted at the start of the Plenary Abstracts Session; Saturday, June 15, 2024, 14:45 CEST, unless the abstract is part of an official EHA Press Briefing in which case the embargo lifts on the date and time of the Press Briefing (if earlier).
 - **For Late-Breaking oral presentations:** The embargo is lifted at the start of the Late-Breaking Oral Session; Sunday, June 16, 2024, 09:45 CEST, unless the abstract is part of an official EHA Press Briefing in which case the embargo lifts on the date and time of the Press Briefing (if earlier).
 - **For press abstracts:** The embargo is lifted at the start of the EHA Press Briefing (date and time to be confirmed).
- This embargo policy covers all abstracts accepted as part of the EHA2024 Hybrid Congress, regardless of the source from which the information is obtained. Third parties are obliged to abide by the Congress Embargo Policy. Should an embargo be broken, both the third party and the person involved will be held responsible and liable.



Timeline

May 3 - 9	Submission website is open
May 10 - 15	Abstract review
By May 24	Announcement allocation of late-breaking abstracts to authors
June 3; 16:00 CEST	Late-breaking abstracts online

Selection procedure

All abstracts submitted for the late-breaking procedure will be reviewed by the Scientific Program Committee (SPC) and the Advisory Board (SPC-AB). After review, the abstracts will be either accepted for oral presentation and included in the program or will be rejected.



Abstract Topics

1. Acute lymphoblastic leukemia - Biology & translational research
2. Acute lymphoblastic leukemia - Clinical
3. Acute myeloid leukemia - Biology & translational research
4. Acute myeloid leukemia - Clinical
5. Chronic lymphocytic leukemia and related disorders - Biology & translational research
6. Chronic lymphocytic leukemia and related disorders - Clinical
7. Chronic myeloid leukemia - Biology & translational research
8. Chronic myeloid leukemia - Clinical
9. Myelodysplastic syndromes - Biology & translational research
10. Myelodysplastic syndromes - Clinical
11. Bone marrow failure syndromes incl. PNH - Biology & translational research
12. Bone marrow failure syndromes incl. PNH - Clinical
13. Myeloma and other monoclonal gammopathies - Biology & translational research
14. Myeloma and other monoclonal gammopathies - Clinical
15. Myeloproliferative neoplasms - Biology & translational research
16. Myeloproliferative neoplasms - Clinical
17. Hodgkin lymphoma - Clinical
18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical
19. Aggressive Non-Hodgkin lymphoma - Clinical
20. Lymphoma biology & translational research
21. Stem cell transplantation - Experimental
22. Stem cell transplantation - Clinical
23. Hematopoiesis, stem cells and microenvironment
24. Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
25. Gene therapy, cellular immunotherapy and vaccination - Clinical
26. Sickle cell disease
27. Thalassemias
28. Enzymopathies, membranopathies and other anemias
29. Iron metabolism, deficiency and overload
30. Infections in hematology (incl. supportive care/therapy)
31. Transfusion medicine
32. Platelet disorders
33. Bleeding disorders (congenital and acquired)
34. Thrombosis and vascular biology
35. Quality of life and palliative care
36. Ethics and health economics
37. Novel technologies, techniques and digital analytical tools in hematology



EHA Copyright

Material published in the Annual Congress Abstract Book is covered by copyright. All rights reserved. No part of the publication may be reproduced, stored in a retrieval system, translated, or transmitted in any form or by any means now or hereafter known, electronic or mechanical, without permission in writing from the publisher, the European Hematology Association (EHA).

Republication & reprints

Authors reusing their own material

Authors have permission to do the following after their article or abstract has been published, either in print or online.

- Reprint the abstract in print collections of the author's own writing.
- Present the work orally in its entirety.
- Use the abstract in theses and/or dissertation.
- Reproduce the abstract for use in courses the author is teaching. If the author is employed by an academic institution, that institution may also reproduce the abstract for course teaching.
- Distribute photocopies of the abstract to colleagues, but only for noncommercial purposes.
- Reuse figures and tables created by the author in future works.
- Post a copy of the abstract on the author's personal website, departmental website, and/or the university intranet. A hyperlink to the abstract / publication on the EHA website must be included.
- Abstracts accepted and presented during the EHA Annual Congress may be submitted as encore abstracts to meetings commencing after the Congress dates, with the reference that it has been accepted and presented at the EHA Annual Congress.
- Authors and third parties wishing to order (commercial) reprints should contact EHA by emailing info@ehaweb.org.
- Third-parties, other than the authors, wishing to re-use parts of the abstract, poster or presentation, need to directly contact the author for permission. EHA will not provide any contact details in line with the GDPR.

Authors reusing their own material in the above ways do not need to contact EHA for permission. For all other uses, the author must request permission from EHA by emailing info@ehaweb.org.

Citations

The author must include the following citation when citing material, after their article or abstract has been published:

Abstract Book:

Author(s), Title, Journal, Year; Volume (Supplement nr): Page(s). Abstract nr XXX.



Translation Rights

EHA permits abstracts to be translated into foreign languages, which can be reprinted for distribution. Please see our terms and conditions below:

- Nothing may be added to or deleted from the original text, figures, references or editorial notes.
- No product advertising or company logos will be permitted in foreign language reprints. No content that was not originally published as part of the abstract may be printed together with the abstract as one printed piece. A tracking number for inventory purposes may be printed on the back of the reprints, but nowhere else.
- If any attachments, such as product information, are to be distributed with the reprinted abstract, the following methods only may be used:
 - Insert product information into reprint as a loose leaf
 - Staple product information to reprint after the translated reprint has been bound
- EHA reserves the right to inspect the content and the packaging for the foreign language edition of the abstract prior to distribution.
- The following disclaimer must be included on the back of all translated reprints. The disclaimer must appear in English, as well as in the language of the reprint.

“© European Hematology Association. Reprinted with permission from the European Hematology Association, which does not endorse any particular uses of this document. The European Hematology Association is not responsible for the completeness or the accuracy of the translation.

For further information, or to request permission to translate an abstract, please contact EHA by emailing info@ehaweb.org.

Applicable law and jurisdiction

These Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the District court in the Hague, the Netherlands.

###